http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022250523-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7890c214f68c5483d2bb60eaff52a6a0 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7008 |
| filingDate | 2022-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ad784265f8be6125200376ca9e24629 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_24ab5fb7ddf008a8c506949343710cf5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf06dc4f407630bd97daec1544dc1bc4 |
| publicationDate | 2022-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2022250523-A1 |
| titleOfInvention | Pharmaceutical kits and products comprising a direct precursor in the formation of glycosaminoglycans and a non-steroidal anti-inflamatory drug as independent compositions, and uses of same |
| abstract | The present invention relates to the development of independent compositions of active pharmaceutical ingredients that are usually combined into a single pharmaceutical form. In particular, the present invention relates to a kit comprising independent pharmaceutical compositions that have a disproportionate ratio in terms of quantity of active ingredients, which implies a potential risk for the health of patients due to the intrinsic actions of each active ingredient. The independent compositions enable patients in need to be dosed in an effective, uniform, safe and protected manner without the possibility of producing degradation substances, in addition to favouring the adaptability and performance of the pharmaceutical product given the possibility of being administered in scheduled dosing periods. |
| priorityDate | 2021-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 230.